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Abstract
Background: Rett syndrome (RTT) is a severe, progressive, neurodevelopmental disorder predominantly observed
in females that leads to intellectual disability. Mutations and gross rearrangements in MECP2 account for a large
proportion of cases with RTT. A limited number of twin pairs with RTT have also been reported in literature.
Case Presentation: We investigated 13 year old, monozygotic twin females with RTT and some noticeable
differences in development using a combinatorial approach of sequencing and Taqman assay. Monozygosity status
of the twins was confirmed by informative microsatellite markers.
Conclusions: The twins shared a de novo deletion in exon 3 in the MBD domain of MECP2. To the best of our
knowledge, this is only the second report of genetic analysis of a monozygotic twin pair.
Background
Rett Syndrome (RTT; MIM # 312750) is a severe progres-
sive neurodevelopmental disorder that predominantly
affects females. It has an estimated global prevalence of
approximately one in 10,000-15,000 female births [1,2]
and one in 100,000 male births [3,4]. Typical/classical
RTT is characterized by normal development up to the
age of 7-18 months; then a period of developmental stag-
nation followed by rapid regression, deceleration of head
growth, stereotypic hand movements, loss of speech and
acquired motor skills. In contrast, atypical RTT refers to a
subset of patients who do not meet all the criteria but
manifest a variant form of the disease which exhibits het-
erogeneity in terms of age of onset, severity and clinical
course [5,6]. Point mutations and insertion/deletion varia-
tions inMECP2 (Xq28) account for approximately 70-80%
of cases with classic RTT [7,8] and a lower percentage of
atypical cases [9-11]. Gross rearrangements in MECP2,
which cannot be detected by sequencing or dHPLC, can
be identified by a range of alternate methods such as
Southern blot analysis [12,13], gene dosage assays with
quantitative fluorescent PCR [14,15], and multiplex liga-
tion-dependent probe amplification (MLPA) [16,17].
These methods contribute to unequivocal diagnosis of an
additional ~10% of mutation negative cases [18]. Exons 3
and 4 in the MECP2 have been identified to be hotspots
for rearrangements [1,2].
A limited number of twin pairs with RTT, all clinically
well characterized, have also been reported in literature.
Some studies have described twins showing almost con-
cordant clinical features suggesting a genetic basis for
RTT syndrome [19,20]. To the contrary, others described
clinical discordance in monozygotic twins with RTT,
with early developmental differences [21,22] and also
with regard to seizures, scoliosis and stereotypic hand
movements during adolescence in a twin pair [23]. How-
ever, genetic analysis has been reported for only in a sin-
gle monozygotic twin pair [24]. This study is a second
report describing the genetic basis of RTT in a 13 year
old monozygotic female twin pair.
Case presentation
The monozygotic twin females were born in an uneventful
pregnancy by caesarean section with each having birth
weight of 2.4 kg. The twins had normal motor milestones
till about two years of age. Regression of milestones was
observed following seizures, the younger of the twins at
two years of age and the elder six months later. They also
show minor phenotypic variation between them. The
older twin had short stature (height -130 cm- < 5th Cen-
tile NCHS); and a head circumference of 51.5 cm; was
non-verbal with poor response to commands; has a
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Vineland Social Maturity Scale (VSMS) score of 19 indi-
cating profound mental retardation. The gait was wide
based with no contractures and she had an attention span
of 10-15 minutes. The younger twin also had short stature
(height - 122 cm < 5th centile) and a head circumference
of 48.5 cm; had a vocabulary of few single words;
responded promptly to commands; as severely mentally
retarded with a VSMS score of 23. She also had a wide
based gait with mild knee contractures; and was on the
move all the time. Both the twins had stereotypic behavior
(hand biting and wringing movements); had thin and
wasted limbs; had no organomegaly or evidence of head
trauma or birth asphyxia; no difficulties in eating, chewing
or swallowing; had normal vision; no sleep disturbances to
date; no scoliosis; both were toilet trained and could indi-
cate their needs well.
Genetic analysis
The study was approved by the institutional ethical com-
mittee. Informed consent was obtained from the parents
and blood samples (and also photographs) were collected
for genetic analysis from the twin pair and parents.
Patients were diagnosed as per criteria previously
described [25]. Ten age and sex matched female healthy
controls with no history of mental illness were also
recruited from the participating hospitals. These healthy
controls were used for normalization of the relative
quantification assay. Fourteen highly polymorphic micro-
satellite repeat markers were genotyped in the patient
family to confirm monozygosity.
a) Mutation Analysis
In order to detect point mutations and small homo-/
heterozygous interstitial deletions/insertions all four
exons of MECP2 were sequenced in both the twins.
PCR amplification of complete exons including exon-
intron boundaries were carried out using published pri-
mers [7] and the amplification products were sequenced
using ABI3700 genetic analyzer.
b) Gene dosage analysis: detection of gene rearrangements
Exons 1 and 2 of MECP2 have been less frequently
reported to harbor any rearrangements to date and there-
fore were not included for gene dosage analysis. Exons 3
and 4, which are known hotspots for rearrangements,
were screened by relative quantification using Real Time
PCR in conjunction with a Taqman method using an ABI
Prism 7900 HT Real Time PCR system. Three probes
were designed to encompass methyl-CpG binding-domain
(MBD), transcriptional repression domain (TRD) and
deletion prone region (DPR) of exons 3 and 4 respectively
using the primer express software (Applied Biosystems)
and their details are given in Table 1. RNAseP was used as
an internal reference for all the experiments. PCR was per-
formed in triplicate with a final reaction volume of 10 μl.
Validation experiments for each of the three primer sets
were set up with RNAseP to compare the efficiencies of
the target primer with the reference primer set. Serial dilu-
tions of a Centre d’Etude Polymorphisme Humaine
(CEPH) genomic DNA control sample (1347-02) was per-
formed with 10-fold dilutions at each step, and each dilu-
tion was run in duplicate for the standard curve
calculation. Gene dosage analysis was done using the com-
parative Ct method [26]. Relative quantity (RelQ) was cal-
culated as, RelQ = 2-(DDCt). A RelQ ratio of around 1.5
represents three copies whereas ~0.5 represents one copy
as compared to the two copies in the calibrator sample.
Results
Microsatellite markers for confirmation of monozygosity
We genotyped 14 microsatellite markers in the two par-
ental samples, of these only nine markers were informa-
tive. These informative markers were genotyped in the
twin pair. We observed identical alleles at all these nine
markers confirming their monozygosity.
Mutation screening
We screened the four exons and exon-intron boundaries
among the twin pair by sequencing. No mutation was
observed ruling out the involvement of any point muta-
tions or small homo-/heterozygous interstitial deletions/
insertions in the twin pair.
Gene dosage analysis
In the absence of any mutation in the four exons of
MECP2, we carried out gene dosage analysis to identify
heterozygous deletions/duplications, if any, in the rear-
rangement hotspot regions of the gene. Amplification
efficiencies of the target and control (RNAseP) primers
were observed to be similar (~96-100% range). This is a
prerequisite for using the comparative Ct method for
gene dosage analysis. To determine the range of RelQ
values in normal population we analyzed 10 healthy con-
trols (5 males and females each). There was no overlap in
the RelQ between the male and female controls, thus
validating the use of this assay for gene dosage. RelQ
values in cases deviating significantly from the controls
were considered as deletions or duplications. A RelQ
ratio of ~1.5 represents three copies (duplication)
whereas ~0.5 represents one copy (deletion) as compared
to the two copies in the female sample.
The RelQ values for the monozygotic twin pair, as
expected, were found to be similar for all the three tar-
get primers (Table 2). However, both the twins showed
deletion (0.60, 0.65) as compared to the normal range
(0.99-1.16) of RelQ for the exon 3 probe in the MBD
domain. Analysis of the parents with the same probe
did not show any deviation from the normal values.
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Conclusions
Mutations/gene rearrangements in MECP2 resulting in
RTT are mostly germ line events resulting in sporadic
cases of RTT. A small proportion of affected sibs but
with unshared mutations with mother implying germline
mosaicism have also been observed [13,27-29]. In addi-
tion, reports of rare cases of inherited mutations also
exist [30,31]. However, in such families, the mothers
showed either very mild [31] or almost unaffected
[32,33] phenotype which has been explained on the
basis of skewed/non-random X chromosome inactiva-
tion [33]. In the case of proven monozygotic RTT twins,
shared mutation may be expected. Probability of mono-
zygosity is > 99.9% when more than five highly poly-
morphic markers have identical genotypes within a twin
pair [34]. Thus, 100% concordance with all the nine
markers in our study confirms the monozygotic origin
of the twin pair.
Mutation screening of the four exons of MECP2 in the
twin pair did not show any point mutation. However,
both monozygotic twins showed a heterozygous deletion
in exon3 identified by Taqman assay (Table 2). The rear-
rangement was not shared with either of the parents,
thus representing a de novo origin of the probable patho-
logical variation in the family. As mentioned earlier,
there were minor phenotypic differences in these twins.
This may either be due to non-random (in)activation of
the paternal/maternal X chromosomes [22] or may be
due to yet poorly understood epigenetic signatures, if
any, at MECP2 locus. The former assumption has partly
been proved by another study where the twin sisters
shared the mutation (R294X), but showed discordant
clinical phenotype; they observed skewing in favour of
the paternal allele in the twin with more severe pheno-
type [24]. Preferential paternal X chromosome involve-
ment has been shown in several other sporadic RTT
cases [35,36]. Twin studies may be useful to understand
the genetic as well as the non-genetic contribution to the
disease phenotype. Discordance witnessed among some
twin pairs including the pair described in this study
warrant further studies to unravel epigenetic mechanisms
influencing RTT phenotype.
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Table 2 RelQ values for Taqman probes in the RTT family under study
Location of Taqman Probe Control Males Control Females Father Mother Twin1 Twin2 Result
MBD 0.38-0.55 0.99-1.16 0.41 1.0 0.60 0.65 Deletion
TRD 0.48-0.63 0.89-0.98 0.48 0.82 0.95 1.04 Normal
DPR 0.43-0.66 0.88-1.13 0.48 0.82 1.04 1.02 Normal
Methyl-CpG binding-domain (MBD), Transcriptional repression domain (TRD) and Deletion prone region (DPR)
Table 1 Details of primers and probes for the Taqman Assay
Exon Domain* Forward Primer sequence Reverse Primer sequence Probe sequence
3 MBD 5’ AGCGGCGCTCCATCATC 3’ 5’ TTCCGTGTCCAGCCTTCAG 3’ 5’ CATGGGTCCCCGGTCAC 3’
4 TRD 5’ GCTCCTTGTCAAGATGCCTTTTC 3’ 5’ CCATGACCTGGGTGGATGTG 3’ 5’ CCCTCAGCCTTGCCC 3’
4 DPR 5’ GCGTCTGCAAAGAGGAGAAGAT 3’ 5’ GCGGGCTGAGTCTTAGCT 3’ 5’ CAGCCGTCGCTCTC 3’
*Probes were labeled at 5’ with FAM as reporter and at 3’ with NFQ as quencher
Methyl-CpG binding-domain (MBD), Transcriptional repression domain (TRD) and Deletion prone region (DPR)
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